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0022-2836 Published by Elsevier Ltd. OpThe modulation of protein–protein interactions (PPIs) by small drug-like
molecules is a relatively new area of research and has opened up new
opportunities in drug discovery. However, the progress made in this area is
limited to a handful of known cases of small molecules that target specific
diseases.With the increasing availability of protein structure complexes, it is
highly important to devise strategies exploiting homologous structure space
on a large scale for discovering putative PPIs that could be attractive drug
targets. Here, we propose a scheme that allows performing large-scale
screening of all protein complexes and finding putative small-molecule
and/or peptide binding sites overlapping with protein–protein binding
sites (so-called “multibinding sites”). We find more than 600 nonredundant
proteins from 60 protein families with multibinding sites. Moreover, we
show that the multibinding sites are mostly observed in transient
complexes, largely overlap with the binding hotspots and are more
evolutionarily conserved than other interface sites. We investigate possible
mechanisms of how small molecules may modulate protein–protein
binding and discuss examples of new candidates for drug design.Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Introduction
Protein–protein interactions (PPIs) play a key role
in numerous biological processes such as cell
proliferation, growth, differentiation, signal trans-
duction and apoptosis; moreover, it has been shown
that PPIs are disrupted in many diseases including
cancer.1,2 This suggests the attractive possibility of
manipulating PPIs for therapeutic intervention.
However, targeting PPIs is more challenging than
traditional drug discovery that, for example, designsdresses:
bi.nlm.nih.gov.
protein interaction;
served Domain
ing Database; GO,
en access under CC BY-NC-Nsmall molecules to bind to enzyme active sites. The
complications arise from the fact that PPI interfaces
are relatively large, less conserved, often flat or more
shallow and featureless in contrast with ligand
binding pockets.3–7 Presently, there are small-
molecule drugs known to affect about 1% of
human proteins,8 and 10–15% of all human proteins
are considered “druggable”.9 The historical record
of drug design and discovery has given rise to the
idea that PPIs are much more intractable with
respect to small-molecule drug discovery.8 Indeed,
for therapeutic use, the chemicals or drugs should be
small enough to get inside the cell and also be able to
affect the large and often shallow PPI interaction
sites.
Nevertheless, there have been a number of studies
that suggest targeting PPIs for treatments for some
human diseases,10–21 showing that protein–protein
interfaces or regions near interfaces might be
inherently flexible or intrinsically disorderedD license.
†All multibinding sites observed in our study for
proteins in the PDB are accessible from http://www.ncbi.
nlm.nih.gov/Structure/ibis/P-D/multibinding.html.
444 Protein–Protein Interactions with Small Moleculesallowing a small molecule to penetrate these
complexes and displace the protein interaction
partner.22–24 Several papers review the progress
made in this research area.8,25–29 Additional evi-
dence that small molecules do not have to cover the
entire protein–protein binding interface but rather
target only a small number of interface residues, the
so-called “binding hotspot” sites, which contribute
the most to the binding energy, has been obtained.30
Many approaches so far have focused on discov-
ering druggable PPIs by in silico screening of small-
molecule libraries and searching the chemical space
of PPI inhibitors. It was found that PPI inhibitors
usually represent relatively large rigid small mole-
cules, containing hydrophobic and aromatic
groups.4–7 A recent study showed that SVM
(support vector machine) kernels can be successfully
used to select molecular descriptors for PPI in-
hibitors, which characterize specific molecular
shapes and the presence of a privileged number of
aromatic groups.9 Molecular dynamics simulations,
drug design and protein docking studies tried to
uncover dynamic and physicochemical properties of
protein–protein complexes to find those regions and
pockets that can be targeted in small-molecule
library screenings.31 Recently, a model was pro-
posed to predict the druggability of pharmaceuti-
cally important proteins based on the crystal
structures of the binding pockets.32 Despite these
efforts, the most comprehensive list of known
structure complexes with small molecules disrupt-
ing protein–protein interfaces is still very limited [27
Protein Data Bank (PDB) complexes in total]26 and is
represented by only eight protein families. More
recently, a database with an extensive analysis of
these known protein–protein interfaces was made
available.33
It is clear that the systematic and large-scale
analysis of experimentally observed protein–small-
molecule and protein–protein complexes is needed
to discover potential protein–protein interfaces
that, at the same time, have tendencies to bind
small molecules. Such an approach has been
undertaken recently by looking for homologous
complexes in a protein structure database with
overlapping protein–protein and protein–small-
molecule binding sites.34,35 This study demonstrat-
ed that sampling of the space of homologs is an
extremely useful and encouraging approach that
not only allowed the recovery of known interac-
tion modulators but also provided a list of
potential drug targets. However, a large source of
error might come from including complexes that
are the result of crystal packing interactions. In this
regard, specific methods have been developed to
predict and confirm the biological relevance of
specific interfaces in crystal structures.36,37 Another
source of annotation errors comes from inferring
that functions and interactions from distant homo-logs are common descents and do not necessarily
imply similarity in function or interactions and that
annotations transferred fromone protein to a homolog
may result in incorrect functional or interolog assign-
ment at larger evolutionary distances.38 In the current
study, we used the homology inference approach and
used our recently developed IBIS (Inferred Biomolec-
ular Interaction Server) method39,40 to find those
protein complexes that can potentially be targeted by
small molecules. To ensure biological relevance of
binding sites to the query, IBIS clusters similar binding
sites found in homologous proteins based on their
sequence and structure conservation, further validates
them using various approaches and finally ranks
binding sites to assess howwell theymatch the query.
We look for those sites that bind both proteins
and small molecules and define them as “multi-
binding sites”. We ask what thermodynamic and
structural properties of protein complexes make
them more targetable by small molecules. We find
that small molecules have a tendency to bind to
hotspot residues and preferentially target weaker
and more transient protein–protein interfaces.
Moreover, we show that multibinding sites are
more conserved than the rest of the interface. From
the most recent update of the protein structure
databank (Research Collaboratory for Structural
Bioinformatics PDB41), we compile a nonredun-
dant set of potential PPI interfaces from 642
proteins representing 60 protein families, with
strong evidence of multibinding and potential
properties of small-molecule PPI inhibitors.Results
Currently, a total of 239,395 protein chains/do-
mains from 61,413 protein structures are present in
IBIS with at least one type of interaction either
observed in their structural complexes or inferred
from their homologs†. Our method allows analyz-
ing the mechanisms of how a small molecule
competes with a natural protein partner.
Observed cases of small molecules modulating
PPIs
First, we focused on those cases where protein–
protein and protein–small-molecule complexes are
available as separate structures in the structure
databases. Some of the known examples are shown
in Fig. 1 with the structure superpositions of the two
Fig. 1. Known cases of binding of small molecules to protein–protein interfaces with a comparison of the crystal
structures of their protein–protein and protein–small-molecule complexes. (a) Small-molecule inhibitor of the ZipA–FtsZ
PPI (PDB IDs: 1Y2G and 1F46). (b) A small molecule bound to adaptive IL2 and IL2R-alpha interface (PDB IDs: 1Z92 and
1M48). (c) Small molecule triggered Bax/Bak-mediated apoptosis in Bcl-2 proteins [Bcl-2, Bcl-x(L) and Bcl-w] (PDB IDs:
2BZW and 2YXJ). (d) A small molecule bound to the N-terminal transactivation domain of human papillomavirus type 11
E2 and inhibits its interaction with E1 (PDB IDs: 1TUE and 1R6N). (e) Small molecule inhibiting the p53–MDM2 to
activate the p53 pathway in cancer cells (PDB IDs: 1RV1 and 1YCR). (f) A small-molecule inhibitor of tumor necrosis
factor-alpha that promotes disassembly of this trimeric cytokine (PDB IDs: 1TNF and 2AZ5).
445Protein–Protein Interactions with Small Moleculesdifferent complexes of the same protein. We first
tested if our method can recover known examples
from the literature of PPIs that are modulated by
small molecules. The method successfully recovered
six out of eight known cases (Table SM1 and Fig. 1).
The interaction between IL2 and IL2-alpha receptor
was not recovered because of a partial Conserved
Domain Database (CDD) domain mapping (see
Materials and Methods). The case of tumor necrosis
factor-alpha trimer dissociation mediated by a small
molecule has been missed due to the stringent
overlap threshold used in our method. In a survey of
all the observed PPI and small-molecule interactions
in the current PDB, 3223 domains/chains were
found to have their observed PPI interfaces overlap
with observed or inferred small-molecule binding
s i tes ; on the other hand, 4532 prote in
domains/chains have their observed small-mole-
cule binding sites overlapping with observed or
inferred PPI interfaces.The same protein may be represented in multiple
structures solved under different conditions or with
mutations and/or in complex with several different
small molecules. To account for this, we inferred PPI
from close homologs with more than 90% sequence
identity and found 6255 chains/domains in PDB
with multibinding interfaces. A few examples are
presented in Table 1, and the complete list can be
accessed from the Web page provided in Supple-
mentary Information.
Binding sites inferred from homologs
For each protein chain in PDB/Molecular Model-
ing Database (MMDB), we assembled a comprehen-
sive list of inferred protein–protein and protein–
small-molecule binding sites using IBIS. Since
inferred binding sites represent the consensus of
binding sites from close homologs, their location
reflects the conformational diversity and variability
Table 1. Protein–protein interfaces overlapping with small-molecule binding sites from very close homologs
PDB Interacting chains Interacting domains
Homolog with bound
small molecule Small molecule
1A14 N:H Sialidase–IgV_H 2C4AA O-Sialic acid
1AY7 A:B RNase_Sa–barstar 1RGEA 2′-Guanylic acid
1EAW A:B Tryp_SPc–KU 1EAXA Benzamidine
1EYM B:A FKBP_C–FKBP_C 1FKIA AC1L9IC3
1F46 B:A ZipA–ZipA 1S1JA CHEMBL1233656
1G5J A:B Bcl-2_like–Bcl-2_BAD 1YSGA 4-(4-Fluorophenyl)benzoic acid
1JSU B:C CYCLIN–CDI 2UUEB GVC
1L6X A:A Ig–Ig 3D6GB CHEMBL1236746
1M9C A:D Cyclophilin_ABH_like–Gag_p24 3CYHA L-Proline
1TGS Z:I Tryp_SPc–KAZAL_PSTI 3LJOA CHEMBL1229618
1VLB A:A Fer2–Ald_Xan_dh_C2 1VLBA 2Fe–2S cluster
1XEV A:B alpha_CA_I_II_III_XIII–alpha_CA_I_II_III_XIII 1ZFQA CHEMBL6685
1XFP L:A LYZ1–Ig 1H6MA Acetylglucosamine
1XX9 B:D Tryp_SPc–ecotin 3BG8A Benzamidine
2E1A D:C WHTH_GntR–WHTH_GntR 2E1AD Selenomethionine
2G2U A:B beta-Lactamase–BLIP 2ZD8A MER
2GPV D:B NR_LBD_ERR–NR_LBD_ERR 1S9QA Cholic acid
2HS1 A:B HIV_retropepsin_like–HIV_retropepsin_like 9HVPB AC1L9IBF
2KNE A:B EFh–ATP_Ca_trans_C 1QIWA AC1L9LMM
2VU8 E:I Tryp_SPc–Pacifastin_I 1PQ7A AC1L9LDG
2W0D A:C ZnMc_MMP–ZnMc_MMP 1UTZA AC1L9MIX
3BIM C:F BTB–BTB 3LBZB Z89
3BX7 A:C Lipocalin–IgV_CTLA-4 3BX8B PE5
3CKI A:B ZnMc_TACE_like–NTR_like 2I47A AC1L9GK4
3DAW A:B ACTIN–ADF 2Q36A KAB
3E1Z B:A Peptidase_C1A–Chagasin_I42 1BP4A AC1L9GMA
3FDL A:B Bcl-2_like–Bclx_interact 1YSGA 4-(4-Fluorophenyl)benzoic acid
3FP7 J:E KU–Tryp_SPc 3LDJB Sucrose octasulfate
3FXI C:B ML–LRR_RI 3FXIC AC1L9IAU
3IG6 B:D Tryp_SPc–Tryp_SPc 1SQTA AC1L9M5D
4CPA A:I M14_CPA–CarbpepA_inh 3CPAA Glycinamide
7GSP A:B Fungal_RNase–fungal_RNase 1RGAA Guanosine
446 Protein–Protein Interactions with Small Moleculesof homologous complexes and at the same time
differences in the sizes of small molecules. A total
of 27,340 protein chains from 501 CDD families
have been determined to contain inferred multi-
binding sites, and a nonredundant set of 642
chains (culled at 50% sequence identity) from 60
families was compiled with multibinding inter-
faces that are biologically relevant according to the
PISA (Protein Interfaces, Surfaces, and Assemblies
server) algorithm.36
Although establishing the biological validity of
each of these multibinding sites still requires
experimental verification, these sites might be used
as starting points to target small-molecule PPI
inhibitors. We provide additional annotation for
the multibinding sites including their PISA status,
biological relevance of small molecules or verifica-
tion of small molecules using DrugBank42 in
Supplementary Materials. For example, of the 642
protein chains, about 400 have at least one multi-
binding site in which the bound small molecule is
also biological.
It should be mentioned that protein structures in
PDB often contain additives, detergents and other
types of substances used for crystallization. These
are not true biological ligands, but they cansometimes be difficult to distinguish from the
biologically relevant ones. In the current study, we
distinguish the most common biological ligands (see
Supplementary Materials). Indeed, the crystalliza-
tion agents, if present, may sometimes provide
additional insights into the binding interfaces on a
protein. For example, the nonbiological small
molecule in the interface between the E2 protein
and E1 helicase of human papillomaviruses proba-
bly defines additional regions of the binding pocket
that could be exploited to design more potent
inhibitors21 (Fig. 1d).
We also note that the PISA program36 is regarded
as a state-of-the-art method for the annotation of
biological assemblies, with an accuracy estimated at
80–90%. Onemight expect that the author-determined
biological units in the PDB files would be the most
reliable. However, it is not difficult to find examples
where the annotations in the PDB file are not
consistent with the authors' own paper; some
authors are quite diligent about this, whereas others
may not be so careful. Moreover, an estimate for the
accuracy of the author-determined annotations is
lacking. Therefore, a highly dependable method
such as PISA provides the most consistent results,
although researchers should be careful and should
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447Protein–Protein Interactions with Small Moleculesconsult the relevant literature when accuracy is
critical.
Multibinding interfaces have a tendency to
include binding hotspots
We calculated a conservation score using the
Shannon entropy with the Henikoff–Henikoff se-
quence weights for each position in a multibinding
site based on the binding site cluster alignments. The
highly conserved residues are most likely critical for
binding and may well be the binding hotspot
residues, namely, those that contribute the most to
the binding energy of the protein complex. We
analyzed the nonredundant set of protein chains in
our data set to check how often the multibinding
residues are predicted to be binding hotspots.
Hotspot residues were predicted using the PCRPi
(Presaging Critical Residues in Protein interfaces)
method, which integrates a number of different
metrics involving sequence and structure, sequence
conservation, “topographical index”, computational
alanine scanning and others into a probabilistic
measure by using Bayesian networks.30 A residue in
an inferred binding site is considered as a hotspot if
the corresponding residue in the homolog contrib-
uting to the site is annotated as a hotpot by PCRPi.
Among the 642 nonredundant protein sequences
with biological interfaces and multibinding sites,
259 chains had at least one hotspot on their multi-
binding inferred site. We found that the association
between multibinding sites and hotspots is statisti-
cally significant (χ2 p-value≪0.01) (Fig. 2), which
points to the critical role of binding hotspots in
modulating PPIs by small molecules.
At the same time, the analysis of residues in the
protein–protein interfaces showed that multibind-ing residues are more evolutionarily conserved than
the rest of the interface (χ2 p-value≪0.01) (Fig. 3),
and hotspots on multibinding interfaces are more
conserved than the rest of multibinding interface (χ2
p-value≪0.01). Previously, it was shown that
binding hotspots are more evolutionarily conserved
than the rest of the interface.43
We mention that small-molecule binding sites can
overlap protein–protein binding sites for different
functional reasons. First, small molecules can repre-
sent natural substrates of enzymes that, in turn, can
be inhibited through the mechanism of competitive
binding by other proteins. A second group consists
of all other cases where small molecules modulate
PPIs. Automatically, classifying a small molecule as
a native substrate is a challenging task, and there is
no such information provided in the PDB files.
Therefore, we used a data source from the previous
study,44 which compared the PDB ligands to small
molecules from the ENZYME and KEGG databases
using graph matching algorithms to assess the
chemical similarity between small molecules. We
mapped these native/cognate ligand annotations to
inferred binding sites in IBIS. A total of 108 proteins
from the nonredundant set of 642 proteins were
found to have at least one multibinding site for a
cognate ligand/native substrate. The analysis of
these multibinding sites with native substrates in
these 108 proteins showed a similar trend of multi-
binding residues to be more conserved and to have a
higher tendency to include binding hotspots (χ2 p-
value≪0.01). However, the first group of enzyme–
substrate complexes showed a lower hotspot fre-
quency but a higher evolutionary conservation of
Fig. 4. GO function distribution of 891 nonredundant protein chains (culled at 50% sequence identity) based on GO slim terms.
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449Protein–Protein Interactions with Small Moleculesmultibinding residues compared to the second
group of multibinding interfaces.
Functional analysis of proteins with
multibinding sites
The functional enrichment of the nonredundant set
of 642 multibinding proteins has been assessed using
a selected list (GO slim) of gene ontology (GO)45
functional terms. We define this as a study group—a
set of multibinding proteins found in PDB from our
study—and a population group—all of the proteins in
PDB. The frequency of annotation to aGO term for the
study group is then compared to the overall
population, which compensates for the functional
bias in the PDB. We used Ontologizer,46 which
performs amodified Fisher's exact testwith correction
for multiple testing and also takes the parent–child
relationship47 in the GO hierarchy into consideration.
GO assignments to PDB entries have been derived
from the “gene_association.goa_pdb” gene associa-
tion file provided by the UniProtKB-GOA group. We
found that metabolic, regulation, transducer activity,
electron carrier activity and multicellular organismal
processes are significantly enriched with multibind-
ing proteins (χ2 p-value≪0.01) (Fig. 4). An analysis
based on the assigned Enzyme Commission48 num-
bers of the nonredundant set ofmultibinding proteins
and the rest of the proteins in PDB showed that
multibinding sites are significantly overrepresented
in enzymes (χ2 p-value≪0.01), that is, protein chains
with assigned Enzyme Commission numbers.
Small molecules modulate transient PPIs
We checked the hypothesis whether the ability of
small molecules to modulate and inhibit PPIs will
depend on the stability of protein–protein com-
plexes. We estimated the free energy of dissociation
ΔGdiss by using the PISA algorithm. We compared
the stability of dimeric complexes containing
multibinding sites against all nonredundant di-
mers in the PDB as determined by PISA. As can
be seen in Fig. 5, dimers with multibinding sites
are less stable compared to the other dimers (t-test
p-value=0.016). Indeed, proteins with multibind-
ing sites constitute a significantly smaller fraction
among permanent protein complexes with the
dissociation constant in the nanomolar-to-picomo-
lar range and ΔGdiss of 20–30 kcal/mol or higher.
Mechanisms of action in the proteins with
multibinding interfaces
A majority of multibinding proteins observed in
structure databases41 include synthetic small mole-
cules targeting protein inhibitor binding sites. The
modulation of PPIs is carried out through disrup-
tion, inhibition, stabilization or allosteric regulation.For example, kirromycin antibiotics such as aurodox
lock EF-Tu (elongation factor-thermo unstable) in its
EF-Tu/GTP conformation, preventing its release
from the ribosome, which illustrates the mediation
of a PPI by a small molecule. Similarly, the fungal
phytotoxin fusicoccin stabilizes the interaction of
14-3-3 with PMA2, a plant proton pump.49 Two
more smallmolecules, pyrrolidone 1 and epibestatin,
have recently been found to stabilize the 14-3-3–
PMA2 interaction.50 Rapamycin, a potent immuno-
suppressive drug, mediates the interaction between
the human signaling proteins FKBP12 and FRAP
that do not normally interactwith one another.51 The
overlap of the rapamycin binding site (1FAP_A:
RAP) with type I TGF-beta receptor in complex with
FKBP12 (1B6C_A:B) suggests a possible role of
rapamycin in TGF-beta signaling. Indeed, FKBP12
binding to the TGF-beta receptor shields a regulatory
segment of the receptor from phosphorylation,
which maintains the receptor in its inactive state.
Therefore, rapamycin bound to FKBP12 should
permit easier activation of the TGF-beta receptor.52
We found that the GTPase (Cdc42) and cell
polarity protein (Par6) PDZ domain interface
(1NF3_A:C) overlaps with the AMP binding site of
a small GTPase Rab1b (3NKV:AMP), suggesting a
possible regulation of Par6 PDZ binding to Cdc42
through AMPylation. It has also been shown that
mutational disruption of Cdc42–Par6 PDZ coupling
leads to inactivation of Par6 in a certain type of
epithelial cells.53 Another example is the cresidine
binding site of Cu–Zn superoxide dismutase (SOD1)
(2WZ0_F:ZZT), which overlaps with the dimer
interface of Cu–Zn superoxide dismutase
(2NNX_D:A). Recently, this binding site has been
450 Protein–Protein Interactions with Small Moleculesannotated as “druggable” for therapeutic purposes
for SOD1-associated motor neuron disease.54 A
complete list of all the protein chains with observed
and inferred multibinding sites is available in
Supplementary Materials.Discussion
The rapid increase in data on protein sequences
and structures is posing new challenges to interpret
and use these data productively. While many
studies have presented novel methods for functional
annotation of these sequences and structures, the
annotations in public databases are still error prone
or often hypothetical. Even when structural data are
available for a particular protein, it can be inconclu-
sive or hard to interpret. Manual curation by an
expert, which is the most rigorous and reliable
means to legitimize a functional site, is limited by
the sheer volume of the data.
Toward addressing this problem, we recently
developed an algorithm (IBIS) to analyze and
conservatively annotate binding sites in proteins
based on knowledge gained via homologous com-
plexes. One important advantage of IBIS-derived
sites is that they are weighted based on their
recurrence in homologous proteins and ranked
using binding site sequence and structure conserva-
tion. In the current study, we used the IBIS database
to discover many protein–protein interfaces that
potentially also bind small molecules. We have
found that about 33% of all protein chains/domains
with both PPI and small-molecule sites inferred
from their homologs have multibinding sites. The
likelihood that these sites are biologically relevant is
increased by the conservative thresholds built into
our method. The GO analysis suggests that multi-
binding sites are often enriched in metabolic
processes. This is also reflected by the significant
number of multibinding sites in GO enzyme
annotations.
An earlier study showed that those positions,
which may bind both small molecules and other
proteins, are less conserved compared to monofunc-
tional sites and also exhibit different amino acid
propensities.34 However, we found that multibind-
ing sites are more evolutionarily conserved and
more likely to contain binding hotspots than other
interface positions that are potentially involved in
binding of one partner. Moreover, it has been shown
previously that hotspots are more conserved than
other interface residues,43 and we confirmed this
result here with regard to hotspots on multibinding
interfaces. Since hotspot residues contribute the
most to the binding energy of PPIs, we suggest
that binding of small molecules to these positions
will have the most disruptive effect on those
interactions. It is especially true if these interactionsare not very strong. Indeed, as was shown in our
study, small molecules mostly bind to transient
protein–protein complexes.
It should be mentioned that the apparent conflict
between our conservation results for multibinding
residues and the results presented previously34 are
undoubtedly due to important differences in meth-
odology between the two studies. For instance, the
earlier work used SCOP and CATH domain
definitions and classifications, which allows for
considerably more remotely related proteins and
may affect the reliability of homology inference. IBIS
uses a conservative threshold for homology infer-
ence (at least 30% sequence identity), and we
observe that multibinding sites are under stronger
evolutionary constraints than even the fairly con-
served family background.
Binding of small molecules to proteins and protein
complexes could cause a shift of equilibrium in favor
of a subset of conformations that has higher or lower
preferences to binding another partner. A small
molecule may bind at a site far from the protein–
protein interface and regulate protein binding
through allosteric mechanisms or might bind at or
near the protein–protein interface and directly
influence the binding. In this study, we focused on
the latter case. We showed that small molecules can
bind to hotspots and through competitive binding
prevent PPI. At the same time, we show examples of
small molecules mediating PPIs. Other mechanisms
of small molecule binding and their functional roles
might be elucidated in future studies when more
structural complexes are available.Materials and Methods
Defining interactions
Protein complexes from the current release of the
MMDB,55 an automatically parsed and validated deriva-
tive of the Research Collaboratory for Structural Bioinfor-
matics PDB,41 are used in this study. PPIs are identified
and analyzed at the domain level. The domain assignment
is performed by searching the protein sequence against a
comprehensive collection of domain models in the CDD.56
PPIs are recorded between different functional domains in
the same chain or between different chains from a protein
complex.
Protein–small-molecule and protein–peptide interac-
tions are defined for a complete protein chain regardless
of its domain annotations. Peptide is defined as a segment
of polypeptide chain of 20 amino acids or fewer. Both
protein–protein and protein–peptide interactions are
considered as PPIs in this study. For small molecules
bound to multiple chains, the interaction is assigned to the
chain with dominant contacts (N75% of the contacts);
otherwise, each protein interaction with the small mole-
cule is recorded separately. An interaction is defined if a
protein domain/chain has at least five residues in contact
451Protein–Protein Interactions with Small Moleculeswith another protein, small molecule or peptide, and two
residues are said to be in contact if any of the heavy-atom
interatomic distances is smaller than 4 Å. The “binding
site” refers to a group of residues that make a contact with
an interaction partner.Inferring binding sites using IBIS
We have used the IBIS method described earlier39,40 to
analyze experimentally observed complexes and at the
same time infer interaction partners and binding sites in
proteins without known complexes by inspecting homo-
logs with known interactions. For a given query protein,
IBIS collects all its homologs with known structures of
complexes from MMDB that have significant structural
similarity and at least 30% sequence identity to the query
as calculated from the structure–structure VAST57 align-
ment. IBIS then clusters binding sites using a complete-
linkage clustering algorithm. Binding site similarity is
assessed based on the structural alignment using similar-
ity scores. At the end of this step, a list of all inferred
binding site clusters and binding partners (chain/do-
mains, small molecules and peptides) is compiled, which is
derived from homologous structural complexes. We refer
to these inferred binding site clusters as inferred binding
sites. For each interaction type (protein–protein, protein–
small molecule and protein–peptide), all binding site
clusters are ranked in terms of their biological relevance
and similarity to the query. The components of the ranking
score include the sequence PSSM score, the average
sequence identity between the query and cluster members
calculated over the whole structure–structure alignment
and the number of interfacial contacts and the average
sequence conservation of binding site alignment columns.
The binding site clusters that contain the observed
interactions of the query are regarded as observed binding
sites, and the rest are defined as inferred binding sites
coming from the homologs.
In addition to the ranking scheme, which aims to rank
the inferred binding sites using evolutionary relatedness
with respect to the query protein, we used other sources.
In the case of protein–small-molecule interactions, small
molecules were all validated and standardized by the
PubChem database,58 which often provides extensive
information on their known biological activities. Small
molecules with less than five heavy atoms and/or having
a molecular mass outside the range of 70–800 Da were
ignored in this study. We also excluded nonbiological
small molecules based on the list used in our previous
study.40 A small-molecule-inferred binding site is deemed
nonbiological if all the bound small molecules in an
inferred binding site are nonbiological.
Likewise for PPIs, the oligomeric states and binding
interfaces were verified using PISA algorithm,36 which
identifies biologically relevant interfaces present in crystal
structures. If all interfaces in an inferred PPI binding site
are invalid according to PISA, the site is deemed
nonbiological.Finding sites that bind proteins and small molecules
To detect those sites that can bind to both protein-
s/peptides and small molecules, for a given protein withknown structure, we extract all IBIS-inferred sites
interacting with other proteins, peptides and small
molecules. An inferred binding site is a union of the
observed binding site residues of the members of an
inferred binding site cluster. The overlap score between
protein–protein binding sites and protein–small-molecule
binding sites is calculated as:
SC =
Nab
Na + Nb − Nab
where Na is the number of residues in protein–protein
binding site “a”, Nb is the number of residues in the
protein–small-molecule binding site “b” and Nab is the
number of residues in the intersection of the binding
sites “a” and “b”, that is, the number of multibinding
residues (as indexed with respect to the query). The
multibinding sites are defined as those having an SC
score greater than 0.5.
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